Trials / Completed
CompletedNCT00140985
Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors (TGFß and VEGF)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0954, losartan potassium/Duration of Treatment: 20 weeks | |
| DRUG | Comparator: amlodipine / Duration of Treatment: 20 weeks |
Timeline
- Start date
- 2000-02-01
- Primary completion
- 2002-01-01
- Completion
- 2002-01-01
- First posted
- 2005-09-01
- Last updated
- 2022-02-16
Source: ClinicalTrials.gov record NCT00140985. Inclusion in this directory is not an endorsement.